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Abstract 
Bacteriophages, or phages, are viruses that specifically infect and kill bacterial cells. 
Phages are the most numerous biological entities on Earth, with an estimated population size of 
1031 (1). Discovery, purification, and characterization of phages illuminate the composition of the 
microbial world and provide potential applications in medicine. To combat antibiotic-resistant 
bacteria, phages are being investigated as supplements or alternatives to antibiotics. Methicillin-
resistant Staphylococcus aureus (MRSA) is a commonly acquired infection in hospitals that has 
become difficult to treat due to its resistance to antibiotics commonly used to treat ordinary S. 
aureus infections (20). Bacteriophage, JB, isolated from dairy cow hair samples by Tyler 
Nygaard at Montana State University, has the ability to infect MRSA USA300 strain 
LAC.  Genome annotation of this phage characterized it as a 42,683 bp circularly permuted 
genome with 68 putative protein coding genes, and a G/C content of 35.2%. Through 
bioinformatic analysis it was discovered that in a cluster of reverse transcribed (genes 30-
33), putative integrase and toxin genes were present (21). In order for this phage to be used 
therapeutically in mammalian organisms, the deletion of these genes is essential to prevent the 
possibility for the phage to produce viable lysogen bacterial cells with enhanced pathogenicity. 
Genetic engineering to remove genes 30-33 was performed using type the type II CRISPR-Cas9 
system to generate a strictly lytic deletion mutant JB bacteriophage, JBΔ30-33. The creation of 
the lytic derivative of JB bacteriophage, JBΔ30-33, was confirmed by clear plaque morphology, 
polymerase chain reaction, and DNA sequencing.  
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Glossary of Terms 
Term Definition 
Bacteriophage A virus that infects and kills bacteria.  
 
Lysogen A bacterium harboring a bacteriophage genome within the bacterial 
chromosome.  
CRISPR-Cas9 A protein/RNA complex that creates double stranded breaks within a DNA 
sequence of interest.  
Toxin  A small molecule, peptide, or protein that is toxic when introduced to body 
tissues by interaction with cellular receptors or enzymes.   
Bacteriophage 
Integrase 
A site-specific recombinase that inserts a bacteriophage genome into a 
bacterial chromosome.  
Antibiotic 
Resistance  
Bacteria or other microorganisms’ that are resistant to antibiotic treatment. 
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1. Background 
1.1. Bacteriophages 
Bacteriophages, or phages, are viruses that specifically infect and kill bacterial cells. 
Phages are the most numerous biological entities on Earth, with an estimated population size of 
1031 (1). Phages were co-discovered by William Twort in 1915 and Felix d’Herelle in 1917 (2,3).  
The genetic material of phages is composed of either DNA or RNA and may be double- 
or single-stranded; however, a vast majority of characterized phages utilize dsDNA (4). Phage 
genomes (nucleic acids) are densely packaged and encompassed by an icosahedral protein capsid 
(4). From the small number of sequenced phage genomes collected, phages have been 
determined to be billions of years old and genetically diverse (5). Phage genomic architectures 
and sequences have distinct evolutionary histories and a mosaicism that suggests extensive 
horizontal genetic transfer (6).  
 There are three virion morphologies of dsDNA phages: Myoviridae, contractile tails built 
on a base plate; Podoviridae, very short tails; and Siphoviridae, long non-contractile tails (4). 
Phages are prevalent in many environmental conditions and are an excellent model for genuine 
scientific discovery; undergraduate students can generate hypotheses about uncharacterized 
phages for research opportunities (7).  
Some phages are strictly lytic while others are termed “temperate.” In the lytic cycle the 
bacteriophage infects the host bacteria cell, uses the cell’s replication machinery to produce 
progeny phage, and leaves the cell after cell lysis. There are five stages of the lytic cycle: 
attachment, entry, phage replication DNA transcription/translation, assembly, and lysis. 
Attachment of the phage occurs when the phage tail proteins bind to specific receptors on the 
host cell’s surface. The bacteriophage injects its dsDNA into the cytoplasm of the host bacteria 
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cell. The host cell’s replication, transcription and translation machinery is forced to make copies 
of the phage’s viral genome as well as viral proteins. Packaging of the viral genome into 
assembled protein capsids produces progeny phage particles. To lyse the bacterium, phage-
encoded proteins that perforate the plasma membrane and the cell wall are expressed (8). Once 
the cell is lysed, progeny phage are released and can infect nearby cells (figure 1). 
 
  
Figure 1. Bacteriophage Lifecycles.  
A diagram of the lytic and lysogenic lifecycles that bacteriophages can undergo (8). 
  A subset of phages, termed “temperate” can undergo both the lytic or the lysogenic 
lifecycles. In the lysogenic cycle, once the bacteriophage DNA enters the host the cell the phage 
DNA is recombined into the bacterial host’s chromosome (8). Integration of the phage genome 
into the host bacterial chromosome occurs by phage-encoded integrase proteins. Integrase 
proteins are site-specific recombinases that recognize short sequences of DNA (~30-40 bp) (9). 
Bacteriophage integrases mediate recombination between phage DNA at the phage attachment 
site, a sequence of bases known as attP, and bacteria DNA, the bacterial attachment site, a 
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sequence of bases known as attB (figure 2) (9). After the bacteriophage’s genome is integrated 
within the bacterial host chromosome it is flanked by the sites attL and attR (9). The attL and 
attR sites are considered hybrid because they contain both the partial attP sequence and attB 
sequence (figure 2) (9).  
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Diagram of Integration/Excision Event. 
A schematic of bacteriophage genome integration and excision events into and out of host bacterial genome 
mediated by integrase and excise proteins (10). 
The integrated phage DNA is termed a prophage and its lytic genes are not expressed to drive 
production of new phage particles; however, prophages are still copied with the host 
chromosome DNA allowing the phage genome to still be reproduced. Some phages can switch 
from the lysogenic cycle to the lytic cycle under stressful environmental conditions or 
stochastically; in both cases the prophage is excised from the host chromosome (9). The attL and 
attR sequences are recognizable by excise, a Recombinational Directionality Factor (RDF) 
(Figure 4) (10,11). The RDF promotes prophage excision by redirecting the integrase to the attL 
and attR sequences (11). After excision from the host chromosome, the phage DNA triggers the 
remaining steps in the lytic cycle (figure 2). 
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1.2. Antibiotic Resistance  
Since the early 1900s, antibiotics have been widely used to treat bacterial infections. 
Antibiotics are defined as molecules that inhibit the growth of or kill microorganisms (11). 
Penicillin, which is produced from a fungus, was first discovered by Alexander Fleming in 1928. 
Since the discovery of antibiotics, there has been the anticipation of antibiotic resistance. During 
Fleming’s Nobel Peace Prize lecture in 1945 (awarded for the discovery of penicillin), he warned 
of the possibility of antibiotic resistance, “Then there is the danger that the ignorant man may 
easily under-dose himself by exposing his microbes to non-lethal quantities of the drug make 
them resistant (12).” The Centers for Disease Control and Prevention (CDC) states that 
penicillin-R Staphylococcus was identified as antibiotic resistant in 1940, three years prior to 
penicillin’s introduction to hospitals in 1943 (13). Antibiotic resistance is a consequence of 
natural selection following random mutation and/or horizontal gene transfer. Bacteria that are 
resistant to an antibiotic due to mutations(s) in a gene survive and pass on the resistant gene to 
other bacteria by horizontal gene transfer or to daughter cells by reproduction. A bacterium is 
classified as a multi-drug resistant bacterium, or a “superbug” if the bacterium carries several 
resistance genes. The overuse of antibiotics as well as lengthy administration periods contribute 
to the increase in antibiotic resistance (14). According to the CDC, each year in the United 
States, at least 2 million people are infected with antibiotic resistant bacteria, and for more than 
23,000 people, the infection is lethal (13). 
1.3. Bacteriophage Therapy 
Shortly after phages were discovered, d’Herelle explored the possibility of treating bacterial 
infections with phages. d’Herelle used phages to treat avian typhosis in chickens, Shigella-
associated dysentery (shigellosis) in rabbits, and bacillary dysentery in humans (shigellosis) (3). 
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Shortly after those experiments, British medical officer Colonel Morison used phage to treat 
cholera outbreaks in India from 1930 to 1935 (15). While phages were commonly used as 
antibacterial agents in the early 1900’s, the discovery of penicillin in 1928 led to widespread 
abandonment of phages as therapeutic agents in Western medicine. The recent development of 
many drug-resistant pathogens has increased the interest to revive and develop phages to treat 
bacterial infections again. Strictly lytic phages are preferable to temperate phages as therapeutic 
agents because of their ability to effectively lyse the bacterial host compared to their temperate 
phage counterparts that allow their bacterial host to persist after the temperate phage DNA is 
integrated into the host genome (16). 
Phages have advantages over traditional antibiotics for bacterial infections because they 
are ubiquitous and host specific. In order to use phages as therapeutic agents, well-characterized 
large phage collections and/or automated pipelines that quickly isolate and identify phages are 
necessary. Phage therapy represents a potential alternative to antibiotics; however, there is a lack 
of clinical studies that were established with quality study design, meaning that the results of 
most studies cannot be assessed as statistically significant. Prior to establishment of 
bacteriophage therapy in clinical settings, research must be conducted to determine their 
effectiveness and ensure that the phage therapy will not negatively affect the patient or elicit 
harmful immune responses. Phage therapy case studies have been performed in recent years 
under extreme circumstances as final attempts to save patients with severe bacterial infections 
when all other treatment options have failed. Other phage therapy studies have been termed 
phase I trials, to ensure the safety of administering phages without serious side effects. Phase II 
trials are needed to determine the effectiveness of phage therapy to garner FDA approval (16). 
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Conventional phage therapy is the topical, oral, or systemic administration of many 
copies of one type of bacteriophage that specifically infects the bacterial infection of the patient. 
However, to reduce the emergence of phage resistant mutants, it is ideal for a bacteriophage 
cocktail (two or more types of phages) to be used at once or to administer the bacteriophage 
along with an antibiotic. Phage cocktails can be specifically tailored to infect more than one 
bacterial species. Phage cocktails can also be used to prevent the development of phage resistant 
mutants during treatment of bacterial infections. The co-administration of a phage and an 
antibiotic requires the host bacterial cell population to perform evolutionary trade-offs that likely 
result in reduction of infection (16).  
A recent phage therapy study published by Strathdee and colleagues (2017) was 
conducted on a 68-year-old diabetic male who exhibited necrotizing pancreatitis complicated by 
a multi-drug resistant Acinetobacter baumannii infection. After a chosen bacteriophage cocktail 
was tested and shown to infect the patient’s specific bacterial strain, the phage cocktail was 
administered intravenously and percutaneously. Results of the phage therapy study were 
promising, showing complete clearance of the bacterial infection (17).  
Another recent bacteriophage therapy study by Hatfull and colleagues (2019) was 
conducted on a 15-year-old female with cystic fibrosis with a disseminated multi-drug resistant 
Mycobacterium abscessus infection. Three phages, Muddy, ZoeJ, and BPs, originally isolated on 
Mycobacterium smegmatis were determined to also infect the patient’s specific bacterial strain. 
After six-months of intravenous administration, twice daily (109 phage particles per dose) of the 
cocktail of wild-type Muddy and engineered lytic derivates of ZoeJ and BPs, the patient showed 
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clinical improvement including sternal wound closure, improved liver function, and substantial 
improvement of infected skin nodules (18).  
1.4. Methicillin- Resistant Staphylococcus aureus 
Methicillin-resistant Staphylococcus aureus (MRSA) infections are a global health concern 
(19). S. aureus can cause complicated infections and are associated with high rates of morbidity 
and mortality. In industrialized nations, S. aureus is the leading cause of bacteremia, which often 
causes metastatic infections such as infective endocarditis, arthritis, and osteomyelitis (20). S. 
aureus bacteremia can progress to complications such as sepsis and/or septic shock. 
 Annually in the United States, about 90,000 individuals suffer from MRSA infections and 
about 20,000 of those infections are lethal (20). The CDC states that approximately 5% of 
patients in hospitals in the U.S. carry MRSA in their nose or on their skin (22). A review of 15 
studies established that between 13 and 74 % of worldwide S. aureus infections are resistant to 
methicillin. The prevalence of MRSA isolates in Europe exhibits a north-south variation, and 7 
of the 29 European countries still report at least 25 % of invasive S. aureus isolates are 
methicillin-resistant. In the US, it was estimated in 2005 that 31.8 per 100,000 people were 
infected by MRSA and 75% of those infections resulted in S. aureus bacteremia (20).   
The incidence of MRSA infections is greatest from healthcare-associated onset acquired 
infections. Patients with MRSA infections obtained from healthcare-associated onset often 
exhibit comorbidities such as diabetes, decubitus, ulcers, chronic renal disease, prior stroke, and 
dementia. The healthcare-associated MRSA strains are commonly associated with pulsed-field 
gel electrophoresis (PFGE) USA100 or USA 200 strains and the community-associated MRSA 
strains are commonly associated with the USA300 or USA400 strains (20).  
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The community-associated strains have a higher expression of toxin producing genes when 
compared to the healthcare acquired strains, suggesting that the community-associated strains are 
more virulent. Colonization of non-invasive MRSA occurs in 1.3 % of the general population, 
the most common site of colonization is the anterior nares, MRSA may also colonize the throat, 
axilla, rectum, groin, or perineum (20).    
1.5. JB Bacteriophage  
 Bacteriophage JB, isolated from dairy cow hair samples by Dr. Nygaard at Montana 
State University in the Voyich lab, has the ability to infect methicillin-resistant S. 
aureus USA300 strain LAC. JB’s siphoviridae morphology was observed with a transmission 
electron microscope (figure 3). The icosahedral capsid was measured at a width of 75 nm, and 
the non-contractile tail length as 160 nm (figure 3) (21).  
JB’s siphoviridae morphology captured by Transmission Electron Microscopy (21). 
  
DNA sequencing and genome annotation characterized JB’s genome as a circularly 
permuted 42,683 bp genome with 68 putative protein coding genes, and a G/C content of 35.2% 
(figure 4) (21).  
Figure 3. Transmission Electron Micrograph of JB.  
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JB bacteriophage’s annotated genome map cropped into four tiers. Bioinformatically called genes are depicted by 
the green and red boxes spanning the length of the genome (21). 
 
1.6. CRISPR-Cas9  
Genetic modification and editing are important biotechnological research tools used to 
understand gene functions and biological mechanisms. In the past, gene editing used tools such 
as restriction enzymes, recombinases, programmable nucleases, and zinc finger nucleases; 
however, these gene editing tools were complex and/or limited in their specificity (22). Once the 
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas (CRISPR 
associated)9 technology that utilized a single programmable guide RNA (sgRNA) (composed of 
crRNA and tracrRNA) was developed by Doudna and colleagues, genomic engineering became 
simplified and specific, eliminating the complexity that previously hampered genetic editing 
(23). In the past eight years since the newly developed CRISPR-Cas systems were first harnessed 
as powerful genomic editing tools, the CRISPR systems have allowed researchers to use the 
Figure 4. Genome Map.  
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CRISPR systems in a wide variety of applications from developing novel genome engineering 
programs to clinical trials involving their potential therapeutic applications (22).   
  CRISPR-Cas9 systems are protein-nucleic acid complexes that provide bacteria and 
archaea adaptive immunity from invasion by foreign nucleic acids such as phages (24). There are 
three known types of CRISPR/Cas systems, Type I, II, and III (24). In nature, CRISPR systems 
are a type of adaptive immune system that use small CRISPR RNAs (crRNAs) and Cas 
nucleases to cleave foreign nucleic acids (24). The system is adaptive because it captures and 
integrates foreign nucleic acid sequences (30-40 nucleotides) called “spacers” into its CRISPR 
loci, between the partially palindromic DNA repeats of crRNA (24). When the foreign nucleic 
acid sequence invades the cell, the host cell liberates the crRNAs and combines with a Cas 
protein to form an effector complex that recognizes the nucleic acid sequence (protospacer) that 
is complimentary to the crRNA (24). 
The type II Cas9 system is the most used CRISPR-Cas system for genome editing. The crRNA 
of this system relies on tracrRNA (trans-activating RNA), which has complimentary sequence to 
the repeat-derived sequences in crRNA (24). The tracrRNA and the precursor crRNA base pair 
to form a mature crRNA and associate with the Cas9 enzyme to form a complex (24). The 
mature crRNA recognizes a short motif known as a protospacer adjacent motif (PAM) in the 
target DNA sequence and guides the Cas9 enzyme to the target DNA sequence to create the 
dsDNA break (24).   
  In many of the CRISPR/Cas systems a PAM sequence is absent from the host genome 
but preserved in the foreign genome, thereby distinguishing between self and non-self (24). In 
the Type II systems, the PAM is a consensus sequence that occurs downstream of the crRNA 
binding sequence within the target DNA (24). The PAM sequence is essential for the Cas9 
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enzyme to introduce dsDNA breaks, and is required to license duplex unwinding, strand 
invasion, and the formation of an R-loop structure (24). The Cas9 protein contains domains that 
are homologous to HNH and RuvC-like endonucleases, and each domain cleaves one strand of 
DNA. The HNH domain cleaves the DNA strand that is complimentary to the sgRNA and 
the RuvC-like domain cleaves the non-complimentary DNA strand (24).   
tracrRNA substantially enhances the specificity and binding of the Cas9 protein to target 
DNA. Cas9 systems alone or Cas9-cRNA have decreased DNA binding at target sequences, 
indicating that tracrRNA enhances target DNA recognition by orienting the crRNA correctly so 
interaction with the complementary strand of DNA can occur. In nature, species that 
have maintained specificity of dual RNA-guided cleavage of DNA indicate that Cas9, tracrRNA 
and crRNA repeat have co-evolved. Additionally, efficient target DNA cleavage occurs 
when there is a contiguous stretch of at least 13 base pairs between the crRNA and the target 
DNA site proximal to the PAM (24).  
Doudna and colleagues (2012), harnessed the CRISPR-Cas9 system to direct the  
Cas endonuclease to a target sequence of plasmid DNA that bears a protospacer sequence 
complimentary to a mature crRNA and a PAM sequence (23).  Genomic editing nucleases, such 
as the Cas9 nuclease, take advantage of innate cellular DNA repair systems (23). The nucleases 
generate the DNA breaks that induce cellular damage responses such as non-homologous end-
joining (NHEJ) or homology-directed repair (HDR) (22). NHEJ response is error-prone and 
often leads to insertion or deletion mutations (indels) within the DNA (22). NHEJ is often 
induced to create gene knockouts by introducing a Cas9 cleavage to an exon to generate frame-
shift mutations to prematurely introduce stop codons and disrupt gene expression 
(22). Megabase-size deletions can also be created by two targeted, double-stranded breaks and 
12 
relying on NHEJ to introduce a large deletion (22). HDR is less error prone; HDR is induced 
after introduction of the Cas9 nuclease and a repair template to the target sequence of DNA. The 
homology-directed repair can result in precise genome alterations such as the deletion of large 
sequences (figure 5) (22).  
 
Figure 5. Schematic of CRISPR/Cas9 Deletion, Insertion, or Modification Event.  
CRISPR/Cas9 creates a double stranded break upstream of the PAM sequence within the target DNA sequence. 
Homologous recombination of the genomic DNA with the provided donor template results in a precise deletion, 
insertion, or modification (22). 
 
Doudna and colleagues devised an effective and simple method to program the Cas9 
endonuclease family with a single guide RNA molecule that directs the Cas enzyme cleavage of 
specific sequences of DNA to generate dsDNA breaks for genome targeting and editing (23).  
1.7. Genomic Editing of Bacteriophages with CRISPR/Cas9 
 The recent ability to harness CRISPR-Cas9 as a tool for genomic engineering, allows 
researchers to efficiently edit bacteriophage genomes to characterize and understand gene 
functions. In nature, CRISPR systems are abundant in a broad range of species (23). The 
CRISPR system is adaptive because it captures and integrates foreign nucleic acid sequences 
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(30-40 nucleotides) called “spacers” into its CRISPR loci, between the partially palindromic 
DNA repeats of crRNA (23). When foreign nucleic acid sequence invades the cell, the host 
cell generates crRNAs that combine with a Cas protein to form an effector complex 
which recognizes the nucleic acid sequence (protospacer) complimentary to the crRNA 
(23). Bacteriophage genomes can be modified to a desired construct by providing a donor DNA 
segment that bears the desired mutations within the protospacer region flanked by sequences that 
are homologous to the phage genome on both sides (22). To construct the desired mutant, the 
host cell uses the donor DNA segment after the Cas9 cleavage as a template for homologous 
recombination (22).  
 Chen and colleagues designed and constructed a CRISPR/Cas9 expression plasmid, 
pCasSA, to harness the CRISPR/Cas9 system for genomic editing in S. aureus (28). The pCasSA 
plasmid contains a strong S. aureus rpsL promoter to drive the expression of the Cas9 protein, a 
strong cap/1A promoter to drive the expression of the gRNA, a BsaI cloning site for the 
assembly of spacers, a XbaI/Xhol cloning site for repair arms, a chloramphenicol (Cm) resistance 
marker for screening in S. aureus, a kanamycin (KanR) resistance marker for screening in 
E.coli, repF, a temperature sensitive origin of replication for S. aureus, and ColE1, a replication 
origin for E. coli (figure 6) (28). 
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pCasSA vector map of the cloning sites and antibiotics resistance markers. The XbaI and XhoI sites are available for 
the insertion of repair arms DNA sequence and the BsaI sites are available for the insertion of gRNA sequence (28). 
 
 JB phage contains a putative gene encoding for an integrase protein; the presence of this 
gene indicates that JB is likely a temperate bacteriophage. In order for JB to be used for 
therapeutic purposes, it is critical that a high proportion of phage infections results in bacterial 
cell lysis is critical for eradication of MRSA bacterial infections. It is therefore essential to delete 
the integrase gene in JB phage in order to create a strictly lytic JB phage derivative. 
Within phage genomes it is not uncommon to find genes that encode putative toxin proteins. 
Abedone and LeJeune (2005) suggest that through genetic symbiosis between phage and bacteria 
after genome integration, toxin genes have remained prevalent in phages. These virulence factors 
contribute to the development of infectious diseases in eukaryotes (24). JB phage encodes a 
putative toxin protein; through CRISPR-Cas9 gene editing technology it is possible to remove 
the toxin gene, which is a necessary step before the JB phage could be used therapeutically in 
humans to treat MRSA bacterial infections.   
Figure 6. pCasSA plasmid.  
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1.8. Project Aims 
Experiments were designed using repair arms to delete the cluster of four reverse genes 
(genes 30-33) within the JB genome after CRISPR-Cas9 mediated breaks (figure 7). 
 
 
 
 
 
Gene number 30- putative integrase, Gene number 31- hypothetical protein with no known function, Gene 
number 32- putative toxin, Gene number 30- putative transcriptional regulator. 
 
1.9. Experimental Design 
A series of steps were planned to (1) construct a plasmid with gRNA and repair arms 
(figure 8); (2) introduce the plasmid into S. aureus RN4220; (3) infect the strain harboring the 
plasmid with the JB bacteriophage (figure 9); (4) isolate released phages by plaque assay on S. 
aureus PS88; and (5) screen resultant plaques for JB bacteriophage deletion mutant with PCR 
and DNA sequencing.  
 
 
 
 
 
 
 
 
 
Schematic of target DNA genomic editing after the introduction of the repair arms and sgRNA into the pCasSA 
plasmid (25). 
 
 
Figure 7. Schematic of the four genes to be deleted from the JB genome.  
Figure 8. pCasSA-mediated genome editing. 
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Schematic of phage engineering after incorporation of the CRISPR/Cas9 expression vector into S. aureus RN4220. 
Expression of the Cas9 complex within S. aureus RN4220 after infection with the JB phage results in a double-
stranded break within the JB DNA sequence that is homologous to the gRNA. Homologous recombination with the 
provided repair arms results in a deletion mutant JB phage (24). 
 
  
Figure 9. Phage Engineering.  
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2. Methods 
2.1. Preliminary bioinformatic analysis of genes 30-33 within the JB 
bacteriophage genome 
Initial JB phage genome annotation by Dr. Gregory determined the location and starts of 
genes 30-33 and their protein coding potential (21). 
Additional bioinformatic analysis of genes 30-33 was done with the NCBI database, 
Basic Local Alignment Sequence Tool (BLAST) (25). Protein BLAST (BlastP) was performed 
by inputting genes 30-33’s amino acid sequences into the BlastP tool (25). The BlastP compared 
the protein sequences of genes 30-33 to sequence databases and calculated the statistical 
significance of sequence alignment (25).  
2.2. Construction of the pHS1 plasmid 
 Purification of the pCasSA plasmid 
pCasSA, CRISPR-based E. coli/S. aureus temperature-sensitive plasmid for genome 
editing in S. aureus was purchased from Addgene (Addgene plasmid #982111; 
http://n2t.net/addgene:98211; RRID: Addgene_98211) (26) (figure 10).  
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Figure 10. pCasSA (28).  
 A vector map of the pCasSA plasmid from Addgene. 
The pCasSA plasmid was received within Escherichia coli in a bacterial agar stab. A 
sterile pipette tip was inserted into the bacterial agar stab, and the E. coli containing the plasmid 
were streaked using sterile technique onto a Luria Broth (LB) plate containing 50 µg/mL 
kanamycin. The plate was incubated at 37oC overnight. Isolated colonies were observed and 
picked into 4 mL of LB broth containing 50 µg/mL kanamycin and incubated overnight at 37oC 
with shaking at 250 rpm. The bacterial cultures were pelleted by centrifugation at 12,000 rpm for 
5 minutes. The supernatant was decanted, and the plasmid was purified from the pelleted cells 
using a Thermo Scientific GeneJET Plasmid Miniprep Kit (K0503).  
 DNA Sequencing of pCasSA as a negative control for repair arms 
and gRNA 
Purified pCasSA plasmid (100 ng/µL in a total volume of 10 µL) and aliquots of primers 
A, D, and F (50 ng/µL in a total volume of 10 µL) were sent to Functional Biosciences  for 
DNA sequencing.  
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 Amplification and Purification of the Left and Right Repair Arms 
 The JB bacteriophage genome six-frame translation and the genome annotation were 
used to determine the location of the four genes to be knocked out (19). Flanking left and right 
repair arm sequences were chosen (~1 kb each) (Appendix A). Primers to isolate the repair arms 
from the JB genome using polymerase chain reaction (PCR) were designed with flanking 
sequences for seamless cloning into the pCasSA plasmid’s XbaI and XhoI cloning sites using 
NEBuilder Hifi DNA Assembly (Appendix B).  
 JB bacteriophage was amplified on S. aureus PS88 Rosenbach (ATCC 33742). The lysate 
was diluted 1:1000 in sterile nuclease-free water for use as a DNA template in the PCR reaction. 
PCR amplification of the left arm was performed by adding 1 µL JB lysate (5.0 x 105 pfu/mL) 
diluted in sterile nuclease-free water (1:1000), 12.5 pmol of primer A (Appendix B), 12.5 pmol 
of primer B (Appendix B), and 12.5 µL of Promega 2X GoTaq Green Mastermix and the final 
volume was brought to 25 µL. PCR amplification of the right arm was performed by the addition 
of 1 µL JB lysate (1:1000) diluted in sterile nuclease-free water, 12.5 pmol of primer C, 12.5 
pmol of primer D, and Promega 2X GoTaq Green Mastermix for a final volume of 25 µL. The 
reactions were placed in a Bulldog Bio LifeECO Thermal Cycler [1 cycle (96oC -2 min.); 30 
cycles (96oC- 15 sec., 60oC- 45 sec, 72o- 1 min 30 sec); 1 cycle (72oC- 5 minutes); indefinite 
hold at 4oC].  
The reaction products were analyzed by agarose gel electrophoresis on a 0.8% agarose 
gel stained with 4x10-4 mg/mL EtBr at 130 V in 1X TBE Buffer. Ten microliters of the PCR 
products were flanked by 0.5 µg/lane of 1 KB GeneRuler Ladder. DNA bands were visualized 
on a Bio-Rad Gel Doc XR.  
To purify the left and right repair arm PCR products, the bands were excised from the gel 
with sterile scalpels. The bands were purified using the ThermoFisher GeneJET Gel Extraction 
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Kit (K0692). To verify efficient recovery of the left and right repair arm DNA fragments, 5 uL 
the purified products plus 1 µL of 6X loading dye were analyzed by agarose gel electrophoresis 
flanked by 0.5 µg/lane of 1 KB GeneRuler Ladder on a 0.8% agarose gel stained with 4x10-4 
mg/mL EtBr at 130 V in 1X TBE Buffer. DNA bands were visualized on a Bio-Rad Gel D XR.  
 Annealing of the Left and Right Repair Arms 
 For efficient cloning of the repair arms into the pCasSA plasmid, the purified 
PCR products of the left and right repair arms were annealed using the NEBuilder Hifi DNA 
Assembly Cloning Kit (NEB #E5520). The annealed product was diluted (1:10) in sterile 
nuclease-free water and used as a DNA template for PCR. PCR amplification of the annealed 
arms was performed by adding 1 µL annealed product (1:10), 12.5 pmol of primer A (Appendix 
B), 12.5 pmol of primer D (Appendix B), and 12.5 µL of Promega 2X GoTaq Green Mastermix 
in a final volume of 25 µL.  The reactions were placed in a Bulldog Bio LifeECO Thermal 
Cycler [1 cycle (96oC -2 min.); 30 cycles (96oC- 15 sec., 60- 45 sec, 720- 1 min 30 sec); 1 cycle 
(72oC- 5 minutes); indefinite hold at 4oC]. To verify successful annealing of the left and right 
repair arms, 5 µL the annealed product, plus 1 µL of 6X loading dye were analyzed by agarose 
gel electrophoresis flanked by 0.5 µg/lane of 1 KB GeneRuler Ladder on a 0.8% agarose gel 
stained with 4x10-4 mg/mL EtBr at 130 V in 1X TBE Buffer. DNA bands were visualized on a 
Bio-Rad Gel Doc XR.  
 Insertion of the Repair Arms into the pCasSA plasmid 
Two micrograms of the pCasSA plasmid were digested with 1 unit of XbaI (New England 
BioLabs) and 5 µL of 10X Cutsmart Buffer (New England BioLabs) in a 50 µL reaction. The 
reaction was incubated at 37oC for one hour, and 1 unit of XhoI (New England BioLabs) was 
added for a sequential digest. The reaction was incubated at 37oC overnight.  The digestion 
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reaction was purified using the QIAquick PCR Purification kit. To maintain the correct pH of the 
purification product, 10 µL of 3M NaOAc was added to the sample to ensure binding of the 
plasmid to the column. To confirm efficient digested plasmid recovery, 5 µL of the purified 
product was analyzed by agarose gel electrophoresis, next to one lane (0.5 µg/lane) of 1 KB 
NEB ladder and electrophoresed on a 0.8% agarose gel stained with 4x10-4 mg/mL EtBr in 1X 
TBE Buffer. DNA bands were visualized on a Bio-Rad Gel Doc XR.  
The annealed repair arms were inserted into the vector at a 1:2 ratio using the NEB Hifi 
DNA Assembly Kit (NEB #E5520). The assembly reaction (2 uL) was subsequently transformed 
into NEB 10-beta Competent E. coli (High Efficiency, NEB #C3019). The transformed cells 
were plated with sterile glass beads on LB plates with 50 µg/mL kanamycin and incubated at 
37oC overnight. To isolate the pHS1 plasmid, half of each isolated colony was picked with a 
sterile pipette into 4 mL LB broth with 50 µg/mL kanamycin and incubated at 37oC with shaking 
at 250 rpm overnight. Bacterial cultures were pelleted by centrifugation at 12,000 rpm for five 
minutes. The supernatant was decanted and the plasmid was purified from the pelleted cells 
using a Thermo Scientific GeneJET Plasmid Miniprep Kit (K0503). The miniprep samples of 
pHS1 were stored at -20oC. 
To screen the bacterial colonies for the pHS1 plasmid, the other half of each isolated 
colony was picked with a sterile pipette into 999 µL of sterile nuclease-free water. PCR 
amplification of the annealed arms was performed to screen the colonies for the pHS1 plasmid 
by adding 1 µL of the suspended colonies, 12.5 pmol of primer A (Appendix B), 0.5 uL of 25 
µM of primer D (Appendix B), and 12.5 µL of Promega 2X GoTaq Green Mastermix in a final 
volume of 25 µL.  The reactions were placed in a Bulldog Bio LifeECO Thermal Cycler [1 cycle 
(96oC -2 min.); 30 cycles (96oC- 15 sec., 60oC- 45 sec, 720- 1 min 30 sec); 1 cycle (72oC- 5 
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minutes); indefinite hold at 4oC]. The reactions were analyzed by agarose gel electrophoresis on 
a 0.8% agarose gel stained with 4x10-4 mg/mL EtBr at 130 V in 1X TBE Buffer. Ten microliters 
of the PCR reactions were flanked by 0.5 µg/lane of 1 KB GeneRuler Ladder. DNA bands were 
visualized on a Bio-Rad Gel Doc XR.  
 Cultures from colonies that were confirmed to contain the pHS1 plasmid were made into 
glycerol stocks; 500 µL of the bacterial culture was mixed with 500 µL of sterile 40% glycerol in 
a 2 mL cryovial. The glycerol stocks of E. coli containing pHS1 were stored at -80oC.  
2.3. Construction of the pHS3 plasmid 
 Creation of the gRNA 
 To generate the pHS3 plasmid, a gRNA (Appendix A) was designed from the JB phage 
genome and ligated into the pHS1 plasmid. The gRNA was designed by identifying a sequence 
within the cluster of four genes to be knocked-out that was upstream of a PAM sequence 5’ to 3 
(located within gene 32 at 29,030-29,050). The oligonucleotides were designed and ordered from 
Integrated DNA Technologies (IDT) (Appendix A). The oligos were resuspended in sterile-
nuclease free water to a concentration of 50 µM. The oligonucleotides were phosphorylated by 
adding 50 µM of primer F (Appendix B) and 50 µM of primer G (Appendix B) 1 µL of 10X T4 
DNA ligase buffer, and 1 µL of 10 U/µL T4 polynucleotide kinase. The phosphorylation reaction 
was incubated at 37oC for one hour. After phosphorylation, the oligonucleotides were annealed 
by adding 2.5 µL of 1M NaCl to the phosphorylation reaction. The sample was transferred to a 
sterile PCR tube and the reaction was placed in a Bulldog Bio LifeECO Thermal Cycler at 95oC 
for 3 minutes and slowly cooled to room temperature. The annealed oligos were diluted 1:20 
with sterile nuclease-free water.  
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 Golden Gate Assembly 
To introduce the gRNA into the pHS1 plasmid, Golden Gate Assembly was used. To a 
sterile PCR tube, 2 µL of 20 fmol pHS1 plasmid, 1 µL of 100 fmol annealed oligos, 1 µL of 10X 
T4 DNA ligase buffer, 0.5 uL of 1 U/uL T4 DNA ligase, and 0.5 µL of BsaI-HFv2 were added. 
The Golden Gate assembly reaction was placed in a Bulldog Bio LifeECO Thermal Cycler at 
(37oC for 2 min, 16oC for 5 min) for 25 cycles, followed by 50oC for 5 min, 80oC for 15 min, and 
held at 10oC.  
 Transforming E. coli with the pHS3 plasmid and screening 
The pHS1/gRNA (pHS3) Golden Gate assembly reaction was subsequently transformed 
into NEB 10-beta Competent E. coli (High Efficiency, NEB #C3019) using the NEBuilder Hifi 
DNA Assembly Kit. The transformed cells were plated with sterile glass beads on LB plates with 
50 µg/mL Kanamycin at 37oC overnight. To purify the pHS3 plasmid, half of each isolated 
colony was picked with a sterile pipette into 4 mL LB broth with 50 µg/mL kanamycin and 
incubated with shaking at 37oC at 250 rpm overnight. Bacterial cultures were pelleted by 
centrifugation at 12,000 rpm for five minutes. The supernatant was decanted, and the plasmid 
was purified from the pelleted cells using a Thermo Scientific GeneJET Plasmid Miniprep Kit 
(K0503). The purified pHS3 plasmid was stored at -20oC. 
 To screen the bacterial colonies for the pHS3 plasmid, the other half of each isolated 
colony was picked with a sterile pipette into 999 µL of sterile nuclease-free water. PCR 
amplification of a region in the plasmid between the left repair arm and gRNA was performed to 
screen for the insertion of the gRNA and to confirm the creation of the pHS3 plasmid by adding 
1 µL diluted colony (1:1000), 12.5 pmol of primer E (Appendix B), 12.5 pmol primer F 
(Appendix B), and 12.5 µL of Promega 2X GoTaq Green Mastermix for a final volume of 25 
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µL. The reactions were placed in a Bulldog Bio LifeECO Thermal Cycler [1 cycle (96oC -2 
min.); 30 cycles (96oC- 15 sec., 52oC- 45 sec, 720- 1 min 30 sec); 1 cycle (72oC- 5 minutes); 
indefinite hold at 4oC]. 
 The reactions were analyzed by agarose gel electrophoresis on a 0.8% agarose gel stained 
with 4x10-4 mg/mL EtBr at 130 V in 1X TBE Buffer. Ten microliters of the PCR reactions were 
flanked by 0.5 µg/lane of 1 KB GeneRuler Ladder. DNA bands were visualized on a Bio-Rad 
Gel Doc XR.  
 Cultures from colonies that were confirmed to contain the pHS3 plasmid were made into 
glycerol stocks, 500 µL of the bacterial culture were mixed with 500 µL of sterile 40% glycerol 
in a 2 mL cryovial. The glycerol stocks of pHS3 were stored at -80oC.  
2.4. Transformation of the pHS3 plasmid into S. aureus 
 Generating High Concentrations of Plasmids for electroporation into 
S. aureus RN4220  
From the E. coli glycerol stock of the pCasSA plasmid, a small scraping was streaked 
onto an LBA plate containing 50 µg/mL kanamycin for isolated colonies and incubated 
overnight at 37oC. Five isolated colonies were picked with a sterile pipette tip into 5 mL of LB 
containing 50 µg/mL kanamycin and incubated at 250 rpm at 37oC overnight. The bacteria were 
pelleted by centrifugation for 5 minutes at 12,000 rpm. The supernatant was discarded and the 
pCasSA plasmid from the first culture was purified using the Thermo Scientific GeneJET 
Plasmid Miniprep Kit (K0503). The purified pCasSA sample from the first culture was used to 
elute the purified plasmid from the second culture of pCasSA. The pCasSA plasmid eluate was 
used to sequentially to elute the purified plasmid from the remaining columns to generate a high 
concentration (~500-1,000 ng/µL) of pCasSA plasmid for electroporation. The steps were 
repeated for the pHS1 and pHS3 plasmids.  
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 Culturing S. aureus RN4220 
The S. aureus RN4220 glycerol stock was stored at -80oC. From the freezer stock of S. 
aureus RN4220, a sterile pipette was used to add a small scraping of the S. aureus RN4220 
glycerol stock to 20 mL of TSB. The culture flask was incubated at 37oC with shaking at 250 
rpm overnight for 12 hours.  
 Generation of Electrocompetent S. aureus RN4220 
Two sterile culture flasks containing 100 mL TSB were inoculated with 1 mL of 
overnight culture of S. aureus RN4220 and incubated at 37oC at 250 rpm until the OD600 reached 
0.5 (~3 hours). The cells were transferred to four sterile 50 mL conical tubes and placed on ice 
for 15 minutes. The cells were pelleted by centrifugation at 12,000 rpm, 10 min, 4oC. The 
supernatant was removed and discarded without disturbing the pellet. Each aliquot was washed 
with 50 mL of ice-cold sterile deionized water. The cells were centrifuged for 10 minutes at 
4,000xg at 4oC. The supernatant was removed and discarded without disturbing the pellet. The 
pellet was resuspended in 25 mL ice-cold sterile deionized water. Two resuspended bacterial 
pellets were combined into one 50 mL conical tube and centrifuged for 10 minutes at 4,000xg at 
4oC. The supernatant was removed and discarded without disturbing the bacterial pellet. The two 
remaining pellets were resuspended in 16 mL ice-cold sterile 10% glycerol, and centrifuged for 
10 minutes at 4,000xg at 4oC. The supernatant was removed and discarded without disturbing the 
bacterial pellet. The pellet was thoroughly resuspended with 1 mL ice-cold sterile 10% glycerol, 
and transferred to a sterile 1.5 mL microcentrifuge tube, and centrifuged for 5 minutes at 5,000xg 
at 4oC. The supernatant was removed without disturbing the bacterial pellet. The pellet was 
resuspended in 700 µL ice-cold sterile 10% glycerol. The bacteria were divided into pre-chilled 
70 µL aliquots in 0.5 mL microcentrifuge tubes and frozen immediately at -80oC.  
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 Transforming pHS3 into S. aureus RN4220 and screening  
 The electrocompetent cells were retrieved from the -80oC and thawed on ice for 10 
minutes. TSA was aliquoted in 250 µL increments into 1.5 mL microcentrifuge tubes and pre-
warmed at 37oC. To the thawed electrocompetent S. aureus, 1.2 ug of plasmid was added and 
gently mixed by pipetting. The transformation mixture was transferred to a pre-chilled 
ThermoFischer Scientific cuvette with a 0.2 cm electrode gap. The cuvette was placed in the 
sample chamber of a Bio-Rad Gene Pulser II/ Pulse Controller Plus/ Capacitance Extender Plus 
and pulsed once at 2.5 kV, capacitor at 25 µF, and parallel resistor at 200 Ohms, yielding a field 
strength of 12.5 kV and a time constant of -2.5 ms. The cells were immediately mixed into the 
250 µL of pre-warmed TSB. The mixture was transferred to a sterile culture tube and incubated 
at 30oC at 500 rpm for 5 minutes and 250 rpm for 55 minutes. The aliquots were plated in 20 µL 
and 200 uL aliquots on TSA containing 10 µg/mL chloramphenicol for 36 hours at 30oC.  
To screen the bacterial colonies for the pHS3 plasmid, 20 colonies were picked with a 
sterile pipette into 999 µL of sterile nuclease free water. PCR amplification of the left and right 
repair arms to confirm the structure of the pHS3 plasmid was performed by adding 1 µL 
resuspended colony, 12.5 pmol of  primer A (Appendix B), 12.5 pmol of primer D (Appendix 
B), and 12.5 µL of Promega 2X GoTaq Green Mastermix to a final volume of 25 µL. The 
reactions were placed in a Bulldog Bio LifeECO Thermal Cycler [1 cycle (96oC -2 min.); 30 
cycles (96oC- 15 sec., 60oC- 45 sec, 720- 1 min 30 sec); 1 cycle (72oC- 5 minutes); indefinite 
hold at 4oC]. The reaction products were analyzed by agarose gel electrophoresis on a 0.8% 
agarose gel stained with 4x10-4 mg/mL EtBr at 130 kV in 1X TBE Buffer; 10 µL of the PCR 
reactions, were flanked by 0.5 µg/lane of 1 KB GeneRuler Plus Ladder. DNA bands were 
visualized on a Bio-Rad Gel Doc XR.   
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  Transformed colonies that were confirmed to contain the plasmid were picked with a 
sterile pipette into 3 mL TSB containing 10 µg/mL of chloramphenicol and incubated overnight 
at 250 rpm at 30oC. The bacterial cultures were made into glycerol stocks: 500 µL of the 
bacterial culture was combined with 500 µL of sterile 40 % glycerol in a 2 mL cryovial. The 
glycerol stocks of plasmids were stored at -80oC.  
2.5. Infection of S. aureus RN4220-pHS3 with bacteriophage JB 
 Liquid infection of S. aureus RN4220-pHS3 with bacteriophage JB 
An isolated colony of S. aureus RN4220-pHS3 was picked into 3 mL of 10 µg/mL 
kanamycin, TSB (supplemented with 25% dextrose and 0.1 M CaCl2) and grown overnight at 
30oC with shaking at 250 rpm. An isolated colony of S. aureus RN4220 was picked into 3 mL of 
TSB++ and grown overnight at 30oC with shaking at 250 rpm. Ten microliters of JB lysate 
(concentration of the JB lysate: 5.0 x 105 pfu/mL) and 3 mL of TSB (supplemented with 25% 
dextrose and 0.1 M CaCl2) were added to 250 µL of S. aureus RN4220-pHS3 and incubated for 
36 hours at 37oC with shaking at 250 rpm. Ten microliters of JB lysate (5.0 x 105 pfu/mL) and 3 
mL of TSB (supplemented with 25% dextrose and 0.1 M CaCl2) were added to 250 µL of S. 
aureus RN4220 and incubated for two nights at 30oC with shaking at 250 rpm.  
 Lysate creation of putative JB deletion mutant (JB30-33) 
After a 36-hour incubation, the liquid JB infection culture of S. aureus RN4220-pHS3 
was centrifuged at 2,000 rpm for 5 minutes. Three milliliters of supernatant were filtered through 
a 0.22 µm filter into a sterile 15 mL conical tube.  
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 Plaque Assay of S. aureus ATCC 33742 (PS88) with bacteriophage JB 
and putative deletion mutant JB30-33 
An isolated colony of S. aureus ATCC 33742 (PS88) was picked into 3 mL of TSB 
(supplemented with 25 % dextrose and 0.1 M CaCl2) and grown overnight at 30oC with shaking 
at 250 rpm. Ten microliters of JB lysate (5.0 x 105 pfu/mL) and 3 mL of TSB (supplemented 
with 25 % dextrose and 0.1 M CaCl2) were added to 250 µL of S. aureus RN4220-pHS3 and 
incubated at room temperature for 15 minutes. Five milliliters of molten top agar (65oC) of 
TSTA (supplemented with 25 % dextrose and 0.1 M CaCl2) , was added to the culture of S. 
aureus RN4220 with JB phage and poured onto a TSA (supplemented with 25 % dextrose and 
0.1 M CaCl2) plate, after the top agar solidified, the plate was incubated overnight at 30oC. Ten 
microliters of JB lysate (5.0 x 105 pfu/mL) and 3 mL of TSB (supplemented with 25 % dextrose 
and 0.1 M CaCl2) were added to 250 uL of S. aureus RN4220 and incubated at room temperature 
for 15 minutes. Five milliliters of molten top agar (65oC) of TSTA (supplemented with 25 % 
dextrose and 0.1 M CaCl2) , was added to the culture of S. aureus RN4220 with JB phage and 
poured onto a TSA (supplemented with 25 % dextrose and 0.1 M CaCl2) plate, after the top agar 
solidified, the plate was incubated at 30oC.  
2.6. Confirmation of deletion mutant JB30-33.  
 Screening plaques for deletion mutant JB30-33 by PCR.  
Plaques from JB30-33 infection on S. aureus ATCC 33742 (PS88) were picked into 50 
µL of sterile nuclease-free water. Plaques from wild-type JB infection of S. aureus ATCC 33742 
(PS88) were picked into 50 µL of sterile nuclease-free water. An isolated colony of S. aureus 
ATCC 33742 (PS88) was picked into 1000 µL of sterile nuclease-free water as a negative 
control. Purified pHS3 was picked into 1000 µL of sterile nuclease-free water as a positive 
control. PCR amplification of the left and right repair arms was used to confirm the presence or 
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absence of genes 30-33 within the JB phage genome. One microliter of template DNA 
(resuspended plaque or plasmid control), 12.5 pmol of primer A (Appendix B), 12.5 pmol of 
primer D (Appendix B), and 12.5 µL of Promega 2X GoTaq Green Mastermix and brought to a 
final volume of 25 µL. The reactions were placed in a Bulldog Bio LifeECO Thermal Cycler [1 
cycle (96oC -2 min.); 30 cycles (96oC- 15 sec., 60oC- 45 sec, 720- 1 min 30 sec); 1 cycle (72oC- 5 
minutes); indefinite hold at 4oC]. The reactions were analyzed by agarose gel electrophoresis on 
a 0.8 % agarose gel stained with 4x10-4 mg/mL EtBr at 130 kV in 1X TBE Buffer, 10 µL of the 
PCR reactions, were flanked by 0.5 µg/lane of 1 KB GeneRuler Plus Ladder. DNA bands were 
visualized on a Bio-Rad Gel Doc XR. 
 DNA sequencing of PCR amplicons from wild-type JB and JB30-33.  
PCR products of amplified sequence from putative deletion mutant JB30-33, wild-type 
JB, S. aureus ATCC 33742 (PS88), and sterile-nuclease free water (figure 28) were purified with 
a QIAquick PCR purification kit. Purified PCR products and 10 µM aliquots of primers A, D, 
and F were sent to Functional Biosciences  for DNA sequencing.  
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3. Results and Discussion 
3.1. Preliminary bioinformatic analysis of genes 30-33 within the JB 
bacteriophage genome 
Annotated gene #30 is 1047 bp in length, 5’ (26,799-27,845) 3’ within the JB genome. 
Bioinformatic analysis of gene #30 revealed that it putatively encodes for a site-specific 
integrase. BlastP analysis of gene 30 confirmed significant alignment (>99 %) for several S. 
aureus-encoded site-specific integrases (figure 11). 
 
Figure showing significant similarity of JB gene 30 protein sequence to site-specific integrases within the 
GenBank database. 
 
Gene #31 is 930 bp in length, 5’ (27,907-28,836) 3’ within the JB genome. Bioinformatic 
analysis of gene #31’s gene product revealed that it putatively encodes domain-containing 
protein without a known function. BlastP analysis of gene #31 protein sequence confirmed 
significant alignment (>98 %) for several S. aureus domain-containing proteins (figure 12). 
 
Figure 11. BlastP analysis of Gene 30.  
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Figure showing significant similarity of JB gene 31 product’s amino acid sequence to domain-containing 
proteins within the GenBank database. 
 
Gene #32 is 459 bp in length, 5’ (28,855-29,313) 3’ within the JB genome. Bioinformatic 
analysis of gene #32’s product revealed that it putatively encodes a toxin protein. BlastP analysis 
of gene #32 protein sequence confirmed significant alignment (>98 %) for several S. aureus-
encoded toxin proteins (figure 13).  
 
 
 
 
 
 
 
 
Figure showing significant similarity of JB gene 32 product’s amino acid sequence to toxins within the GenBank 
database. 
 
 
Figure 12. BlastP analysis of Gene 31. 
Figure 13. BlastP analysis of Gene 32.  
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Gene #33 is 315 bp in length, 5’ (29,335-29,649) 3’ within the JB genome. Bioinformatic 
analysis of gene #33’s product revealed that it putatively encodes a helix-turn-helix 
transcriptional regulator protein. BlastP analysis of gene #33’s protein sequence significant 
alignment (>98 %) for several S. aureus encoded helix-turn-helix transcriptional regulator  
proteins (figure 14). 
Figure showing significant similarity of JB gene 32’s amino acid sequence to helix-turn-helix transcriptional 
regulator proteins within the GenBank database. 
 
3.2. Construction of the pHS1 plasmid 
 Purification of the pCasSA plasmid 
Isolated colonies were grown from the E. coli bacterial stab on an LBA plate containing 
50 µg/mL kanamycin suggesting the presence of the pCasSA plasmid (figure 15).  
 Figure 15. E. coli containing the pCasSA plasmid. 
A streak plate showing isolated colonies of E. coli containing the pCasSA plasmid.  
Figure 14. BlastP analysis of Gene 33.  
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Following purification of the pCasSA plasmid from liquid cultures of the isolated 
colonies of E. coli, Nanodrop analysis determined the concentration of the purified plasmid to 
be 160.8 ng/µL with a 260/280 ratio of 1.95 (figure 16).  
 
 
  
 
 
 
 
Graph and DNA concentrations of the pCasSA plasmid following Nanodrop analysis. 
 
 DNA sequencing of pCasSA as a negative control for repair arms and 
gRNA 
To establish the purified plasmid lacked DNA sequences similar to JB Bacteriophage, 
DNA Sequencing reactions were run. As expected, DNA sequencing of the purified pCasSA 
plasmid did not produce a DNA sequence from primers A (figure 17). The sequencing results 
show that the repair arms are not within the template pCasSA plasmid. 
 
 
The figure shows sequencing results from pCasSA with primer A. 
Figure 16. Purified pCasSA plasmid.  
Figure 17. DNA Sequencing of pCasSA.  
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DNA sequencing of the purified pCasSA plasmid also did not produce a DNA sequence 
from primer F (figure 18). The sequencing results show that the gRNA is not within the template 
pCasSA plasmid. 
 
The figure shows sequencing results from pCasSA with primer F. 
 
 Amplification and Purification of the Left and Right Repair Arms 
 Polymerase chain reaction amplification of the left and right repair arms yielded DNA 
bands at the expected sizes of 906 bp and 971 bp, respectively (figure 19). The gel 
electrophoresis image demonstrates the successful amplification of the left and right flanking 
sequences of the genes of interest (30-33).  
 
 
 
 
 
 
Figure 18. DNA Sequencing of pCasSA.  
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Gel a.) Gel electrophoresis of left and right repair arms amplified from JB lysate with Polymerase Chain 
Reaction; L- GeneRuler 1 kb DNA ladder, 1- Left repair arm (expected size = 906 bp), 2- Right repair arm 
(expected size= 971 bp). Gel b.) Gel electrophoresis of left and right repair arms after excision and purification from 
gel a; L- GeneRuler 1 kb DNA ladder, 1- Left repair arm (expected size = 906 bp), 2- Right repair arm (expected 
size= 971 bp). 
 
 Annealing of the Left and Right Repair Arms 
DNA assembly of the left and right repair arms yielded a DNA band at the expected size 
of 1,877 bp (figure 20). The presence of the band at 1,877 bp indicates that the left and right 
repair arms were covalently joined.  
 
 
 
 
 
 
Gel electrophoresis of annealed repair arms after DNA assembly; L- GeneRuler 1 kb DNA ladder, 1-annealed left 
and right repair arms (expected size = 1,877 bp). 
 
Figure 19. Gel Electrophoresis Images of Left and Right Repair Arms. 
Figure 20. Gel Electrophoresis Images of Annealed Left and Right Repair Arms. 
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 Insertion of the Repair Arms into the pCasSA plasmid 
Supercoiled and circularized plasmids electrophoretic mobility vary from linear; purified 
plasmids often show two bands (figure 21, lane 1). Linearization of the pCasSA plasmid 
occurred after restriction enzyme digestion with XbaI and XhoI and was visualized with gel 
electrophoresis. The linearized band was observed at the expected size of 10,231 bp (figure 21). 
 
 
 
 
 
 
 
Gel a.) Gel electrophoresis of linearized pCasSA; L- GeneRuler 1 kb DNA ladder, 1- Circularized and supercoiled 
pCasSA (expected size= 10,240 bp) 2- linearized pCasSA (expected size= 10,231 bp). Gel b.) Gel electrophoresis of 
linearized pCasSA after excision and purification from gel a; L- GeneRuler 1 kb DNA ladder, 1- linearized pCasSA 
(expected size = 10,231 bp bp). 
 
To create pHS1, linearized plasmid and repair arms were joined by NEB Hi-Hi DNA 
Assemby and transformed into E. coli. The resultant colonies of E. coli that putatively contained 
the pHS1 plasmid grew on an LB plate containing 50 µg/mL of kanamycin (figure 22).  
 
  
 
 
 
Left plate- Isolated colony growth of E. coli putatively containing pHS1. Right Plate- Negative control 
plate with minimal colony growth. 
Figure 21. Gel Electrophoresis image of linearized pCasSA.  
Figure 22. Colonies of E. coli putatively containing the pHS1 plasmid. 
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Polymerase chain reaction to screen for the repair arms (expected size of 1,877 bp) of the 
pHS1 plasmid within isolated E. coli colonies (figure 22) using primers A and D, revealed the 
expected product size for the presence of the pHS1 plasmid within 16 of 20 picked colonies after 
transformation (refer to figure 23). Colonies picked from the pCasSA (negative control plate) 
(figure 22) did not yield bands for the repair arms. The positive controls of the purified 
assembled arms yielded bands of the expected size, 1,877 bp (figure 23).  
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L- GeneRuler 1 kb ladder, 1-20- picked colonies of the putative pHS1 plasmid (figure 22, left plate), 21-22 
– picked colonies of negative control, vector only (figure 22, right plate), 23-24- picked colonies of the negative 
control, pCasSA plasmid commercially available within E. coli (refer to figure 15), 25-26- positive control, purified 
assembled arm products. 
 
 
 
 Confirmation of the repair arms within the pHS1 plasmid 
DNA sequencing results of the pHS1 plasmid with primer A (figure 24) (Appendix B) 
aligned with the JB wild-type sequenced genome repair arms using BlastN sequence analysis, 
confirming the presence of the repair arms within the pHS1 plasmid (figure 24). 
 
 
 
 
 
Figure 23. Gel Electrophoresis of PCR products to screen for the presence of pHS1 within E. coli.  
39 
 
 
 
 
 
 
DNA sequencing results of the pHS1 plasmid from primer A. 
 DNA sequencing of the pHS1 plasmid as a negative control for gRNA 
As expected, DNA sequencing of the purified pHS1 plasmid did not produce a DNA 
sequence from primer F (figure 25) confirming the absence of the gRNA sequences within the 
pHS1 plasmid.  
 
 
DNA Sequencing results of the pHS1 plasmid with Primer F. 
3.3. Construction of the pHS3 plasmid 
 Transforming E. coli with the pHS3 plasmid and screening 
Following Golden Gate assembly of the gRNA into the pHS1 plasmid (pHS3), the 
plasmid was transformed into E. coli via heat-shock. Isolated colonies that putatively contained 
the pHS3 plasmid were observed after overnight growth on an LB plate containing 50 µg/mL of 
Figure 24. DNA Sequencing results of pHS1.  
Figure 25. DNA Sequencing of pHS1.  
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kanamycin and no colonies were visualized on a negative control Golden Gate Assembly 
reaction of linearized pHS1 plasmid without a gRNA insert (figure 26).  
 
 
 
 
 
 
Left plate- The negative control plate of vector only (pHS1) without gRNA insert yielded no colonies.   
Right plate-Isolated colonies were observed on the LB plate containing the transformed cells with the pHS3 plasmid.  
 
 Three colonies from the right plate were screened by PCR using primers E and F to 
confirm the presence of the gRNA within the pHS3 plasmid yielded bands of the expected size 
of 500 bp (figure 27).  
 
 
 
  
  
 
 
 
 
 
 
 
 
 L- 1 kb NEB ladder, 1- pHS3 sample #1 (expected size = 500 bp), 2- pHS3 sample #2 (expected size = 500 
bp), 3- pHS3 sample #3 (expected size =500 bp), 4- pHS1 (negative control), 5- pCasSA (negative control), 6- water 
(negative control). 
  
Figure 26. Image of E. coli containing the pHS3 plasmid.  
Figure 27. Gel Electrophoresis Image of Polymerase Chain Reactions to Screen for gRNA within the pHS3 
plasmid.  
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 Confirmation of the repair arms and gRNA within the pHS3 plasmid 
DNA sequencing results of the pHS3 plasmid with primers A (Appendix B) aligned with 
the JB wild-type sequenced genome repair arms using BlastN sequence analysis confirming the 
presence of the repair arms within the pHS3 plasmid (figure 28).  
 
 
DNA Sequencing of the pHS3 plasmid with primer A. 
DNA sequencing results of the pHS3 plasmid with primer F (Appendix B) aligned with 
the JB wild-type sequenced genome repair arms using BlastN sequence analysis confirming the 
presence of the gRNA within the pHS3 plasmid (figure 29). 
 
 
Figure 28. DNA Sequencing of pHS3.  
42 
 
 
 
 
DNA Sequencing results of the pHS3 plasmid with primer F. 
 
3.4. Insertion of the pHS3 plasmid into S. aureus RN4220 
 Transforming pHS3 into S. aureus RN4220 and screening.  
S. aureus RN4220 transformed with the pHS3 plasmid yielded isolated colonies that 
putatively contained pHS3 on a TSA (supplemented with 25 % dextrose and 0.1 M CaCl2) plate 
with 10 µg/mL of chloramphenicol. No colonies were observed on a TSA (supplemented with 25 
% dextrose and 0.1 M CaCl2) plate with 10 µg/mL of chloramphenicol of wild-type S. aureus 
RN4220 (negative control) (figure 30).  
 
 
 
Figure 29. DNA Sequencing of pHS3.  
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Left plate- No colonies were observed on the negative control plate of S. aureus RN4220.  
Right plate- Isolated colonies of S. aureus RN4220 putatively containing the pHS3 plasmid were observed.  
 
Polymerase chain reactions to screen for the presence of the pHS3 plasmid using primers 
A and D within the S. aureus RN4220 colonies yielded bands of the expected size (1,877 bp) on 
gel electrophoresis for at least 8/20 selected colonies indicating the presence of the pHS3 
plasmid within S. aureus RN4220 (figure 31, lanes 1, 2, 3, 11, 13, 14, 18 and 20).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 30. Image of TSA plates (10 µg/mL chloramphenicol) containing isolated S. aureus RN4220 colonies 
containing the pHS3 plasmid.  
*    *    *    *    *    *    *    
*    
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L- 
GeneRuler 1 kb Plus DNA Ladder, 1-20 picked colonies after electroporation of pHS3 into S. aureus RN4220 
(expected size = 1,877), 21- purified pHS3 plasmid, positive control (expected size= 1,877), 22- picked colony of S. 
aureus RN4220, negative control, 23- water, negative control. *- positive PCR amplicon.  
 
 
3.5. Infection of S. aureus RN4220-pHS3 with bacteriophage JB 
 Liquid Infection of S. aureus RN4220-pHS3 with bacteriophage JB 
Liquid culture infection (10 uL) of JB in S. aureus RN4220-pHS3 and S. aureus RN4220 
were observed after the two-day incubation period. The S. aureus RN4220-pHS3 cultures after 
JB liquid infection appeared clear and after centrifugation (2,000 rpm for 5 minutes) no bacterial 
pellet was observed (figure 27). The absence of bacterial growth from S. aureus RN4220-pHS3 
culture after JB liquid infection suggested the presence of deletion mutant JB (JB30-33) with 
strictly lytic capabilities. The S. aureus RN4220 culture after JB liquid infection appeared cloudy 
Figure 31. Gel Electrophoresis Image of Polymerase Chain Reactions to Screen for the presence of pHS3 
within S. aureus RN4220.  
*    
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and after centrifugation (2,000 rpm for 5 minutes) a bacterial pellet was observed (figure 32). 
The presence of bacterial growth from S. aureus RN4220 culture after JB liquid infection 
suggests the formation of lysogens, which was expected due to wild-type JB’s lysogenic 
capabilities.  
  
 
 
 
 
 
 
 
The image shows the difference in bacterial growth after JB infection of S. aureus RN4220 (left culture) compared 
to S. aureus RN4220-pHS3 (right culture).  
 Plaque assay of S. aureus ATCC 33742 (PS88) with bacteriophage JB 
and putative deletion mutant JB30-33.  
After incubation, the resultant plaques from wild-type JB on S. aureus ATCC 33742 
(PS88) appeared small and turbid/cloudy, which is indicative of a temperate bacteriophage. In 
contrast, the resultant plaques from lysate of putative deletion mutant JB30-33 on S. aureus 
ATCC 33742 (PS88) appeared small and clear, which is indicative of a lytic bacteriophage 
(figure 33), suggesting deletion of genes 30-33 and JB’s ability to form lysogens.  
Figure 32. Liquid infection of JB in S. aureus RN4220-pHS3 and S. aureus RN4220.  
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a.) Resultant plaques from putative deletion mutant JB30-33. b.) Resultant plaques from wild-type JB. 
 
3.1. Confirmation of deletion mutant JB30-33  
 Screening plaques for deletion mutant JB30-33 by PCR  
Polymerase chain reactions were used to screen for the presence or absence of genes 30-
33 within the JB phage genome yielded the expected results (figure 34). The plaque from the 
putative deletion mutant JB30-33 yielded a band of approximately 2,000 bp, indicating the 
deletion of genes 30-33 (figure 34). Plaques from the wild-type JB phage yielded a band of 
approximately 5,000 bp, indicating the presence of genes 30-33 (figure 34). The purified pHS3 
as a positive control plasmid yielded a band of approximately 2,000 bp (figure 34). The negative 
controls of an isolated colony from S. aureus ATCC 33742 (PS88) and sterile nuclease-free 
water yielded no bands (figure 34).  
 
 
 
 
 
Figure 33. Plaque assay infections on S. aureus ATCC 33742 (PS88).  
a. b. 
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L-GeneRuler 1 kb Plus DNA Ladder, 1- putative deletion mutant JB30-33 plaque, 2-4 wildtype JB plaque, 5- pHS3 purified 
plasmid, 6-PS88 colony, 7- water. 
 
 DNA sequencing of PCR product from wild-type JB and JB30-33.  
DNA sequencing results of wildtype JB (5,000 bp) product with primer A (Appendix B) 
aligned with the JB wildtype sequenced genome using BlastN sequence analysis (figure 35).  
 
 
 
 
 
 
 
 
 
 
 
DNA sequencing of the wildtype JB (5,000 bp) PCR product from primer A aligned with the full genome JB 
sequence using BlastN sequence analysis. 
 
DNA sequencing results of wildtype JB (5,000 bp) product with primer F (Appendix B) aligned 
with the JB wildtype sequenced genome using BlastN sequence analysis (figure 36).  
 
Figure 35. DNA sequencing results of wildtype JB (5,000 bp) PCR product.  
Figure 34. Gel electrophoresis image of Polymerase Chain Reactions to screen for the presence or absence of 
genes 30-33 in phage plaques. 
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 Figure 36. DNA sequencing results of wildtype JB (5,000 bp) PCR product.  DNA sequencing of the wildtype JB (5,000 bp) PCR product from primer F aligned with the full genome 
JB sequence using BlastN sequence analysis. 
 
 DNA sequencing results of deletion mutant JB30-33 product with primer A (Appendix 
B) aligned with the JB wildtype sequenced genome using BlastN sequence analysis confirming 
the presence of the repair arms (figure 37).  
 
 
 
DNA sequencing of the JB30-33 (2,000 bp) PCR product aligned with the full genome JB sequence using 
BlastN sequence analysis. 
 
Figure 37. DNA sequencing results of JB30-33 (2,000 bp) PCR product.  
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DNA sequencing results of deletion mutant JB30-33 product with primer F (Appendix B) did 
not produce a DNA sequence confirming the absence of genes 30-33 (figure 38).  
 
 
 
DNA sequencing of the JB30-33 (2,000 bp) PCR product did not produce a DNA sequence. 
 
  
Figure 38. DNA sequencing results of JB30-33 (2,000 bp) PCR product.  
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4. Conclusion 
Staphylococcal bacteriophage JB, isolated from dairy cow hair samples, has the ability to 
infect methicillin-resistant Staphylococcus aureus (MRSA). After genome annotation, 
bacteriophage JB was determined to be a temperate phage that contains putative toxin and 
integrase genes. In order to use JB as a potential phage for mammalian organisms, deletion of the 
toxin and integrase coding genes is essential to produce a safe strictly lytic phage. 
This study used a commercially available CRISPR/Cas9 expression plasmid, pCasSA, to 
generate the pHS3 plasmid. The pHS3 plasmid contains a gRNA, a sequence specific to a cut site 
within the genes of interest upstream of a PAM sequence to guide the Cas enzyme to the genes 
30-33 within the JB genome. The pHS3 plasmid also contained 1,000 bp sequences flanking the 
genes of interest (repair arms) to mediate homologous recombination after the Cas enzyme’s 
double-stranded break of the JB genome, effectively removing genes the toxin and integrase 
genes. The creation of the pHS3 plasmid with the repair arms and gRNA was confirmed by PCR 
and DNA Sequencing.  
Transformation of the pHS3 plasmid into S. aureus RN4220 generated S. aureus 
RN4220-pHS3 which was subsequently infected with the JB bacteriophage. Liquid infection of 
JB in S. aureus RN4220-pHS3 generated the deletion mutant JB30-33. Plaque assays of 
JB30-33 on S. aureus PS88 showed a clear plaque morphology indicating a lytic bacteriophage, 
in contrast to wildtype JB turbid plaque morphology indicating a temperate bacteriophage. The 
creation of deletion mutant JB30-33 was confirmed by PCR and DNA Sequencing.  
The genetically engineered derivative of JB phage, JB30-33, had the problematic 
integrase and toxin genes removed for safety and demonstrated lytic capabilities in liquid 
infections and plaque assays. Further characterization of JB30-33 is necessary to determine if 
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JB30-33 host range on clinical isolate strains of S. aureus has altered infectivity compared to 
wildtype JB. Future studies of JB30-33 and wildtype JB can be performed in vitro on cell 
cultures and in vivo on murine organisms infected with S. aureus to determine its safety and 
efficacy in phage therapy. Further characterization of JB30-33 can be performed by imaging 
JB30-33 by transmission electron microscopy.  
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5. Appendix A: Repair Arms and gRNA isolated from the JB genome. 
Left Repair Arm: 
5’CTGCAGTAGAGCAAAGTACGTTAGAAAAACAAAAAGAAAGATTGCACTTTCAAGA
TAATATTAAAAAAGCACATAAAAAAGTATATCGTGAATTTGTTAGTAAACAAAATA
AAGATAAAAAGGGGAAGGATAAATGATGTTTATAACTGGAATAGTGATATCGTTAG
TTGTAATCTTGATAGCTTCATATTTTTCCTTTGTTTTAACAACATTAATTATAAGCGA
AGATTTTAGTGACCGAGTTACTTTAAAAGTAGCATTTATCTTACCAATAATATTAAT
ATCCCTATCCATTCGTGCATGTTTAGAAAACCTAAGGAGTAATAAACAACTTGCTAA
AACAGCATTTAAAATGGCTACTACACAATATCCTTCAGTGGTAACAATGTTCATAGG
TATGGTTAAAGACCATCAAGCACAAGTCCACTGTTTTGGTGAATCTACCTATACCTA
TAACCAAAATAAAGAAAACCTAATATTAAAAAAAGACATAAATAAGTCATGGTTAA
ATTCATTAAAGAATTTGAAGTCACTTATTAAATCAGAAGGATTTAAAAAGAATTTTT
TAAATAACTTAGCTGAAGCTTAAGTTCTCGTATTACCTTCGATGATTATGAATTTTGC
TCAGCATGTAAAACCACACCACCTATTAATTTAGGAGTGTGGTTATTTTAATATATG
AAGCTAAAATAACTACAAATGATACCATTTTTGATACCATTTTGTTGTAAAACAGAA
AAAATAAGGAAAATAAAAAAGGCAAAAAAACGCATTAAATCAACGTTTATTGTCTC
ATGAAATTTAAATGTATATAAATTTCACTTCCCATGGGTCATTATGAATTCTTATTTT
AGGCTTGTTATTAC 3’ 
Right Repair Arm:  
5’GTTTACTTTATGTGTTGACACTTTACTTTTAGTGTAGTAAATTAGATGCATACCTTA
CAAGGAGGTGACAACATGACAGATACAATTGAGGCATTTTCTCTAAAGGGTGCGCG
AAATGAATTTGATTACACGCAAGAGCAAATAGCTGATAAATTAGGGGTTTCTCGAG
CACAGTATATTGCGTGGGAAAAAGGTGATGTAATACCTAAAAGCATGGTAGTTTAT
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GCTTTAGCTTACATCTATGGTATTAACGCTGACTTATTAAGAGTCAGCAAAAAAATT
TAAAACTAACTTCACTTAAAGTGAAGTTGTGTAAAAACACGACAAAAGAAAAACAA
ACTATTTAAAAGGAGGAACTCAGATGCAAGCATTACAAACATTTAATTTTGAAGAAT
TACCAGTAAGAACATTAACAGTAAATGAGGAACCGTATTTTGTAGGGAAAGATGTA
GCAGATATTCTAGGTTACAAAAATGGCAGTCGTGATATTAACGCTCATGTTGATGCA
GAAGATAAGCTGACGTACCAAATCAGTACCGCAGGTCAAAGACGAAATCAAACAAT
CATCAACGAATCGGGTTTATACAGCCTAATCTTCTCATCAAAACTAGAATCAGCTAA
ACGATTCAAACGTTGGGTAACTTCAGACGTCCTACCCGCTATTCGAAAACACGGTAT
CTACGCAACAGACAATGTAATTGAACAAACATTAAAAGATCCAGACTACATCATTA
CAGTGTTGACTGAGTATAAGAAAGAAAAAGAGCAAAACTTACTTTTACAACAAGAA
ATTGGAGAGCTAAAACCCAAAGCAGACTATGTAGATGAAATCTTAAAGTCAACTGG
AACATTAGCTACAACTCAAATCGCGGCAGACTACGGTATATCAGCACAAAAGTTAA
ACAAACTACTACACGAAGCTAGATTACAACGAAAAGTGAATAAACAGT 3’ 
gRNA:  
5’ CAAAGCTTCTACAATTTCGCGTAATGG 3’  
            3’CGAAGATGTTAAAGCGCATTACCGAAA 5’  
*underlined PAM sequence 
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6. Appendix B: Primers  
6.1. Table I  
Primer Name 
Primer Sequence 
(5’to 3’) 
Melting 
Temperature 
(Tm) 
G/C 
Content 
A 
(Left Repair Arm 
Forward) 
GATCTGTCCATACCCATGG
TCTGCAGTAGAGCAAAGT
AC  
64.8oC 48.7 % 
B 
(Left Repair Arm 
Reverse)  
TGTCAACACATAAAGTAA 
ACGTAATAACAAGCCTAA 
AATAAGAATTCATAATGA
CC  
62.5oC 62.5 % 
C 
(Right Repair Arm 
Forward)  
GTTTACTTTATGTGTTGAC
AC TTTACTTTTAGTG  
55.4oC 29.4 % 
D 
(Right Repair Arm 
Reverse) 
AAGATACAGGTATATTTTT 
CTGACTGTTTATTCACTTT 
TCGTTGTAATC  
60.7oC 28.6 % 
E 
(Confirm guide) 
GATTCACCAAAACAGTGG
ACT 
54.5oC 42.9 % 
F 
(Forward gRNA) 
CAAAGCTTCTACAATTTCG
CGTAATGG 
53.9oC 43.5 % 
59 
G 
(Reverse gRNA) 
CGAAGATGTTAAAGCGCA
TTACCGAAA 
54.1oC 43.5 % 
 
*underlined sequences are homologous to pCasSA cloning sites  
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7. Appendix C: Media 
Tryptic Soy 
Broth ++ 
(TSB ++) 
To 1 L of sterile ddH20, 30 g Tryptic Soy Broth (Sigma-Aldrich) were added. 
The solution was stirred until fully dissolved and heated until it came to a 
boil. The solution was autoclaved on a liquid cycle for 20 minutes. Prior to 
use, 25 mL/L of a 25 % sterile solution of dextrose and 10mL/L of a sterile 
0.1 M CaCl2 solution was added. TSB ++ was stored in 4oC. 
Tryptic Soy 
Agar ++ 
(TSA ++) 
To 1 L of sterile ddH20, 40 g Tryptic Soy Agar (Sigma-Aldrich) were added. 
The solution was stirred until fully dissolved and heated until it came to a 
boil. The solution was autoclaved on a liquid cycle for 20 minutes. Once the 
solution was cool to the touch, 25 mL/L of a 25 % sterile solution of dextrose 
and 10mL/L of a 0.1 M CaCl2 sterile solution were added. The mixture was 
poured directly into Petri dishes and stored in 4oC or stored in a sterile 
container at room temperature.  
Top Agar ++ 
(TSTA++)  
A 1:1 solution of TSA++: TSB++ is combined and the mixture is kept molten 
at 65oC or stored at room temperature.  
CaCl2 (0.1 M)  1.47 g of Calcium chloride was added to 100 mL of  ddH20 and stirred until 
fully dissolved. The solution was autoclaved on a liquid cycle for 20 minutes. 
 
 

